DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lokivetmab
Lokivetmab
18 December 2020 – to Date)
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Atopic Dermatitis in Animals and People: an Update and Comparative Review
World Congress Veterinary Dermatology (WCVD) Summary by Dr Carmen Lorente, DVM, Phd, Dipecvd EBVS® European Specialist in Veterinary Dermatology
Clinical Efficacy of Oclacitinib and Lokivetmab in Dogs with Canine Atopic Dermatitis
Farmaatsia- Terminoloogia Teine, Täiendatud Trükk
Therapeutic Complications and Follow-Up in a Dog with Atopic Dermatitis
Lecture Overview
Regulation of Skin Barrier Function Via Competition Between AHR Axis
United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
Evaluation of the Clinical Efficiency of Lokivetmab in Client Privately Owned Atopic Dogs – Multicenter Study
2017 Proceedings Book
(INN) for Biological and Biotechnological Substances
Clinical Efficacy of Oclacitinib and Lokivetmab in Dogs with Canine Atopic Dermatitis
New Advances in Canine Allergic Disease
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Top View
6.6.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
Antikörpertherapie
A Blinded, Randomized Clinical Trial Evaluating the Efficacy and Safety Of
Pharmacotherapy of Canine Atopic Dermatitis - Current State and New Trends
Vergleich Der Zulassungen Von GVO- Produkten in Der EU Und Der Schweiz
Mouse Models of Atopic Dermatitis
Introduction
Tumor Microenvironment the Role of Interleukins – Part B Advances in Experimental Medicine and Biology
ATC Vet 2021 Atccode Atcdescription Atcdescriptionsi QA ALIMENTARY TRACT and METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL in PRESNOVE
(INN) for Biological and Biotechnological Substances
AR Annexes 2017 Collated
CYTOPOINT, INN-Lokivetmab
View Consolidated Schedules
Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases
Annexes to the Annual Report of the European Medicines Agency 2020
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri